Copaxone and Injection site discharge - a phase IV clinical study of FDA data

Summary:

Injection site discharge is reported as a side effect among people who take Copaxone (glatiramer acetate), especially for people who are female, 40-49 old, have been taking the drug for 10+ years also take Ampyra, and have Migraine.

The phase IV clinical study analyzes which people have Injection site discharge when taking Copaxone. It is created by eHealthMe based on reports of 56,345 people who have side effects when taking Copaxone from the FDA, and is updated regularly.

What is Copaxone?

Copaxone has active ingredients of glatiramer acetate. It is often used in multiple sclerosis. eHealthMe is studying from 56,931 Copaxone users. Check the latest studies of Copaxone.

What is Injection site discharge?

Injection site discharge is found to be associated with 185 drugs and 158 conditions by eHealthMe. Check the latest studies of Injection site discharge.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 27, 2026

56,345 people reported to have side effects when taking Copaxone.
Among them, 22 people (0.04%) have Injection site discharge.

Could Copaxone cause Injection site discharge?

Among these 22 people:

How long have people been on Copaxone when they have Injection site discharge? *

What is the gender of people who have Injection site discharge when taking Copaxone? *

female: 80 %
male: 20 %

What is the age of people who have Injection site discharge when taking Copaxone? *

What are other drugs people take besides Copaxone? *

What are other side effects people have besides Injection site discharge? *

Injection Site Urticaria (rash of round, red welts on the skin at injection site): 4 people, 18.18%
Injection Site Pain: 3 people, 13.64%
Memory Loss: 3 people, 13.64%
Injection Site Necrosis (death of body tissue at injection site): 3 people, 13.64%
Chest Pain: 3 people, 13.64%
Injection Site Discoloration: 3 people, 13.64%
Indigestion: 3 people, 13.64%
Panic Disorder: 3 people, 13.64%
Gait Disturbance: 3 people, 13.64%
Injection Site Vesicles (fluid- or air-filled cavity or sac at injection site): 3 people, 13.64%

What are the existing conditions these people have? *

Sleep Disorder: 1 person, 4.55%
Migraine (headache): 1 person, 4.55%

* Approximation only. Some reports may have incomplete information.

Do you take Copaxone and have Injection site discharge?

- Check whether Injection site discharge is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Copaxone:

Copaxone (56,931 reports)

Browse all side effects of Copaxone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Injection site discharge:

Injection site discharge (185 drugs)

Browse all the conditions that are associated with Injection site discharge:

Injection site discharge (158 conditions)

Related publications that referenced our studies

Michaud CJ, Bockheim HM, Nabeel M, Daum TE, "Diagnosis of Exclusion: A Case Report of Probable Glatiramer Acetate-Induced Eosinophilic Myocarditis", Case reports in neurological medicine, 2014 Jul .
Michaud CJ, Bockheim HM, Nabeel M, Daum TE, "Diagnosis of Exclusion: A Case Report of Probable Glatiramer Acetate-Induced Eosinophilic Myocarditis", Case reports in neurological medicine, 2014 Jul .

How the study uses the data?

The study uses data from the FDA. It is based on glatiramer acetate (the active ingredients of Copaxone) and Copaxone (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.